Patents/Assignees

Nammi Therapeutics, Inc.

9 patents in portfolio

US12311010utility2025
Formulated And/or Co-formulated Liposome Compositions Containing Toll-like Receptor(“tlr”) Agonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof
0 cites
US12286403utility2025
Formulated And/or Co-formulated Liposome Compositions Containing IDO Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof
0 cites
US12162958utility2024
Fusion Protein Composition(s) Comprising Masked Type I Interferons (IFNA and IFNB) for Use in the Treatment of Cancer and Methods Thereof
0 cites
US12059470utility2024
Formulated And/or Co-formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof
0 cites
US11896646utility2024
Formulated And/or Co-formulated Liposome Compositions Containing Toll-like Receptor (“TLR”) Agonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof
0 cites
US11833209utility2023
Formulated And/or Co-formulated Liposome Compositions Containing PD-1 Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof
0 cites
US11801304utility2023
Formulated And/or Co-formulated Liposome Compositions Containing TFGB Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof
0 cites
US11744874utility2023
Formulated And/or Co-formulated Liposome Compositions Containing Toll-like Receptor (“TLR”) Agonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof
0 cites
US11679141utility2023
Formulated And/or Co-formulated Liposome Compositions Containing Toll-like Receptor (“TLR”) Agonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof
0 cites